IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v529y2016i7586d10.1038_nature16508.html
   My bibliography  Save this article

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Author

Listed:
  • Shaokun Shu

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Charles Y. Lin

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Housheng Hansen He

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School
    Dana-Farber Cancer Institute, Harvard School of Public Health
    Princess Margaret Cancer Center/University Health Network)

  • Robert M. Witwicki

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Doris P. Tabassum

    (Dana-Farber Cancer Institute)

  • Justin M. Roberts

    (Dana-Farber Cancer Institute)

  • Michalina Janiszewska

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Sung Jin Huh

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Yi Liang

    (Princess Margaret Cancer Center/University Health Network)

  • Jeremy Ryan

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Ernest Doherty

    (Dana-Farber Cancer Institute
    Harvard University)

  • Hisham Mohammed

    (Cancer Research UK, Cambridge Institute, University of Cambridge)

  • Hao Guo

    (Dana-Farber Cancer Institute, Harvard School of Public Health)

  • Daniel G. Stover

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Muhammad B. Ekram

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Guillermo Peluffo

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Jonathan Brown

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Clive D’Santos

    (Cancer Research UK, Cambridge Institute, University of Cambridge)

  • Ian E. Krop

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Deborah Dillon

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Michael McKeown

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Christopher Ott

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Jun Qi

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Min Ni

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Prakash K. Rao

    (Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute)

  • Melissa Duarte

    (Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute)

  • Shwu-Yuan Wu

    (Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center)

  • Cheng-Ming Chiang

    (Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center)

  • Lars Anders

    (Whitehead Institute for Biomedical Research)

  • Richard A. Young

    (Whitehead Institute for Biomedical Research)

  • Eric P. Winer

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • Antony Letai

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School)

  • William T. Barry

    (Brigham and Women’s Hospital, Harvard Medical School
    Dana-Farber Cancer Institute, Harvard School of Public Health)

  • Jason S. Carroll

    (Cancer Research UK, Cambridge Institute, University of Cambridge)

  • Henry W. Long

    (Dana-Farber Cancer Institute
    Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute)

  • Myles Brown

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School
    Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute)

  • X. Shirley Liu

    (Dana-Farber Cancer Institute, Harvard School of Public Health
    Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
    Broad Institute)

  • Clifford A. Meyer

    (Dana-Farber Cancer Institute, Harvard School of Public Health)

  • James E. Bradner

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School
    Broad Institute)

  • Kornelia Polyak

    (Dana-Farber Cancer Institute
    Brigham and Women’s Hospital, Harvard Medical School
    Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
    Broad Institute)

Abstract

BET inhibitors that target bromodomain chromatin readers such as BRD4 are being explored as potential therapeutics in cancer; here triple-negative breast cancer cell lines are shown to respond to BET inhibitors and resistance seems to be associated with transcriptional changes rather than drug efflux and mutations, opening potential avenues to improve clinical responses to BET inhibitors.

Suggested Citation

  • Shaokun Shu & Charles Y. Lin & Housheng Hansen He & Robert M. Witwicki & Doris P. Tabassum & Justin M. Roberts & Michalina Janiszewska & Sung Jin Huh & Yi Liang & Jeremy Ryan & Ernest Doherty & Hisham, 2016. "Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer," Nature, Nature, vol. 529(7586), pages 413-417, January.
    • Handle: RePEc:nat:nature:v:529:y:2016:i:7586:d:10.1038_nature16508
    DOI: 10.1038/nature16508
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature16508
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature16508?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Di Yu & Yingying Liang & Claudia Kim & Anbalagan Jaganathan & Donglei Ji & Xinye Han & Xuelan Yang & Yanjie Jia & Ruirui Gu & Chunyu Wang & Qiang Zhang & Ka Lung Cheung & Ming-Ming Zhou & Lei Zeng, 2023. "Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    2. Andrew J. Tao & Jiewei Jiang & Gillian E. Gadbois & Pavitra Goyal & Bridget T. Boyle & Elizabeth J. Mumby & Samuel A. Myers & Justin G. English & Fleur M. Ferguson, 2023. "A biotin targeting chimera (BioTAC) system to map small molecule interactomes in situ," Nature Communications, Nature, vol. 14(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:529:y:2016:i:7586:d:10.1038_nature16508. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.